Advertisement

Pediatric Cardiology

, Volume 32, Issue 3, pp 342–353 | Cite as

Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer

  • Barry H. Trachtenberg
  • David C. Landy
  • Vivian I. Franco
  • Jacqueline M. Henkel
  • Elliot J. Pearson
  • Tracie L. Miller
  • Steven E. Lipshultz
Riley Symposium

Abstract

Anthracycline chemotherapeutic agents are widely used to treat childhood cancers, helping to create an increasing population of childhood cancer survivors. Cardiac complications can occur years after exposure to anthracyclines and are a leading cause of noncancerous morbidity and mortality in this population. The mechanism of its cardiotoxicity is not completely known, although oxidative stress is believed to play a significant role. This pathway and other nonoxidative mechanisms are reviewed. Several risk factors such as age, dose, female gender, and concomitant radiation therapy are known, but the relative risks of many comorbidities such as diabetes and hypertension are not well studied. No standard, evidence-based guidelines for appropriate screening methods to detect cardiotoxicity exist. Periodic imaging with echocardiography or radionuclide angiography is appropriately recommended for long-term survivors but is of limited use during therapy. Biomarkers such as cardiac troponins and brain natriuretic peptides may aid in detecting cardiotoxicity. Studies investigating the use of agents such as angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers to treat anthracycline cardiotoxicity have shown promise, but more data are needed. Structural analogs such as epirubicin were developed to minimize cardiotoxicity but have not sufficiently reduced it. Liposome-encapsulated anthracyclines have shown a considerable decrease of cardiotoxicity in adults without sacrificing efficacy, but the data related to children are sparse. The only agent proven to be cardioprotective is the iron chelator, dexrazoxane. Studies have shown that dexrazoxane is safe and significantly reduces the incidence of cardiotoxicity. Dexrazoxane should be considered for pediatric oncology protocols using anthracyclines that include longitudinal assessment.

Keywords

Anthracyclines Cardiotoxicity Dexrazoxane 

References

  1. 1.
    Adams MJ, Lipshultz SE (2005) Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 44:600–606PubMedCrossRefGoogle Scholar
  2. 2.
    Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10:391–399PubMedCrossRefGoogle Scholar
  3. 3.
    Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention, and management. Expert Opin Pharmacother 8:1039–1058PubMedCrossRefGoogle Scholar
  4. 4.
    Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale BL, Clavell LA, Larsen EC, Moghrabi A, Sampson Y, Schorrin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB (2008) Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 26:1106–1111PubMedCrossRefGoogle Scholar
  5. 5.
    Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168–175PubMedGoogle Scholar
  6. 6.
    Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, Hallowell S, Addonizio LJ, Canter CE (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505–511PubMedCrossRefGoogle Scholar
  7. 7.
    Bu’Lock FA, Mott MG, Oakhill A, Martin RP (1999) Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol 20:252–263PubMedCrossRefGoogle Scholar
  8. 8.
    Cardinale D, Sandri MT, Colombo A, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin-I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–2754PubMedCrossRefGoogle Scholar
  9. 9.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474–2481PubMedCrossRefGoogle Scholar
  10. 10.
    Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220PubMedCrossRefGoogle Scholar
  11. 11.
    Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SAM, Fuster V, Jacobs AK, Gibbons RJ, Russell RO (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 16:1091–1110PubMedGoogle Scholar
  12. 12.
    Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:114–121PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Strarling RC, Towbin J, Virmani R (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 28:3076–3093PubMedCrossRefGoogle Scholar
  14. 14.
    Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Grumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83:1077–1084PubMedCrossRefGoogle Scholar
  15. 15.
    De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anserva P (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121:276–292PubMedCrossRefGoogle Scholar
  16. 16.
    Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M (2008) Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 130:688–695PubMedCrossRefGoogle Scholar
  17. 17.
    Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65:128–135PubMedCrossRefGoogle Scholar
  18. 18.
    French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679–688Google Scholar
  19. 19.
    Gabizon AA, Lyass O, Berry GJ, Wildgust M (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 22:663–669PubMedCrossRefGoogle Scholar
  20. 20.
    Geyer H, Caracciolo G, Abe H, Wilanksy S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Senguota PP (2010) Assessment of myocardial mechanics using speckle-tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 23:351–369PubMedCrossRefGoogle Scholar
  21. 21.
    Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777–3784PubMedCrossRefGoogle Scholar
  22. 22.
    Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27:53–68PubMedCrossRefGoogle Scholar
  23. 23.
    Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML (1976) The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37(2 Suppl):1070–1078PubMedCrossRefGoogle Scholar
  24. 24.
    Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE (1990) Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144–147PubMedCrossRefGoogle Scholar
  25. 25.
    Greenlee H, Hershman DL, Jacobson JS (2009) Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat 115:437–452PubMedCrossRefGoogle Scholar
  26. 26.
    Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu Z, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243PubMedGoogle Scholar
  27. 27.
    Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, Gude NA, Thistlethwaite PA, Sussman MA, Gottlieb RA, Gustafsson AB (2010) Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 121:675–683PubMedCrossRefGoogle Scholar
  28. 28.
    Italian Multicentre Breast Study With Epirubicin (1988) Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol 6:976–982Google Scholar
  29. 29.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 5:277–300CrossRefGoogle Scholar
  30. 30.
    Jurcut R, Wildiers H, Ganame J, D’hooge J, Paridaens R, Voigt JU (2008) Detection and monitoring of cardiotoxicity: what does modern cardiology offer? Support Care Cancer 16:437–445PubMedCrossRefGoogle Scholar
  31. 31.
    Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258–2262PubMedCrossRefGoogle Scholar
  32. 32.
    Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234–235:119–124PubMedCrossRefGoogle Scholar
  33. 33.
    Kanter MM, Hamlin RL, Unverferth DV, Davis HW, Merola AJ (1985) Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol 59:1298–1303PubMedGoogle Scholar
  34. 34.
    Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15:1544–1552PubMedGoogle Scholar
  35. 35.
    Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517–528PubMedCrossRefGoogle Scholar
  36. 36.
    Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA (2005) Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207:436–444PubMedCrossRefGoogle Scholar
  37. 37.
    Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S (2009) Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18:218–224PubMedCrossRefGoogle Scholar
  38. 38.
    Levitt G, Anazodo A, Burch M, Bunch K (2009) Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer 45:3027–3034PubMedCrossRefGoogle Scholar
  39. 39.
    Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL (2008) Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics 121:e1470–e1477PubMedCrossRefGoogle Scholar
  40. 40.
    Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279:8290–8299PubMedCrossRefGoogle Scholar
  41. 41.
    Lipshultz SE, Colan SD (2004) Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 22:769–773PubMedCrossRefGoogle Scholar
  42. 42.
    Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815PubMedCrossRefGoogle Scholar
  43. 43.
    Lipshultz SE, Sanders SP, Colan SD, Goorin AM, Sallan SE, Krischer JP (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433–437PubMedGoogle Scholar
  44. 44.
    Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Ssnders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743PubMedCrossRefGoogle Scholar
  45. 45.
    Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin B, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20:1677–1682PubMedCrossRefGoogle Scholar
  46. 46.
    Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153PubMedCrossRefGoogle Scholar
  47. 47.
    Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629–2636PubMedCrossRefGoogle Scholar
  48. 48.
    Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Sone SM, Gelber RD, Colan SD (2005) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20:4517–4522CrossRefGoogle Scholar
  49. 49.
    Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD (2005) Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115:1613–1622PubMedCrossRefGoogle Scholar
  50. 50.
    Lipshultz SE, Walker VE, Torres SM, Walker DM, Barry E, Miller TL, Scully RE, Sallan SE (2007) Frequent mitochondrial DNA mutations and polymorphisms in long-term survivors of childhood acute lymphoblastic leukemia. Blood 118:824AGoogle Scholar
  51. 51.
    Lipshultz SE, Alvarez JA, Scully RE (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525–533PubMedCrossRefGoogle Scholar
  52. 52.
    Lipshultz SE, Rusconi P, Scully RE (2008) Chapter 18: assessment of cardiotoxicity during anticancer therapy. In: Januzzi JL, Bayes-Genis A (eds) NT-proBNP as a biomarker in cardiovascular diseases 2008. Prous Science. S.A.U., Barcelona, pp 1–15Google Scholar
  53. 53.
    Lipshultz SE, Scully RE, Smith HM, Anderson B, Safa R, Miller TL, Lipsitz SR, Sallan SE, Sawyer DB (2009) Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia (abstract). 5th world congress of paediatric cardiology and cardiac surgery (PCCS2009). Cairns, Australia, p 133Google Scholar
  54. 54.
    Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale U, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE (2010) Diagnostic value of cardiac troponin-T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reactive protein during doxorubicin therapy in children with acute lymphoblastic leukemia (abstract). Circulation 122:A20432Google Scholar
  55. 55.
    Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD (2010) Assessment of dexrazoxane as a long-term cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: a prospective, randomized, multicenter trial. Lancet Oncol 11:950–961PubMedCrossRefGoogle Scholar
  56. 56.
    Lowis S, Lewis I, Elsworth A, Weston C, Doz F, Vassal G, Bellott R, Robert J, Pein F, Ablett S, Pinkerton R, Frappaz D (2006) A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer 95:571–580PubMedCrossRefGoogle Scholar
  57. 57.
    Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF (2007) Topoisomerase IIbeta-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67:8839–8846PubMedCrossRefGoogle Scholar
  58. 58.
    Mariotto AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L, Feuer EJ (2009) Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 18:1033–1040PubMedCrossRefGoogle Scholar
  59. 59.
    Meinardi MT, Van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, De Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753PubMedGoogle Scholar
  60. 60.
    Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, Smithson WA, Robison LL (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163–3172PubMedGoogle Scholar
  61. 61.
    Miller TL, Lipsitz SR, Lopez-Mitnik G, Hinkle AS, Constine LS, Adams MJ, French C, Proukou C, Rovitelli A, Lipshultz SE (2010) Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 19:2013–2022PubMedCrossRefGoogle Scholar
  62. 62.
    Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229PubMedCrossRefGoogle Scholar
  63. 63.
    Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606PubMedCrossRefGoogle Scholar
  64. 64.
    Nakamae H, Tsumura K, Terada Y, Nakane R, Nakamae M, Ohta K, Yamane T, Hino M (2005) Notable effects of angiotensin II receptor blocker, Valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492–2498PubMedCrossRefGoogle Scholar
  65. 65.
    Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD (2000) Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 6:115–119PubMedGoogle Scholar
  66. 66.
    Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582PubMedCrossRefGoogle Scholar
  67. 67.
    Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek RJ Jr, Cusack BJ (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 169:168–176PubMedCrossRefGoogle Scholar
  68. 68.
    Petko C, Minich LL, Everitt MD, Holubkov R, Shaddy RE, Tani LY (2010) Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol. Pediatr Cardiol 31:780–784PubMedCrossRefGoogle Scholar
  69. 69.
    Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815PubMedCrossRefGoogle Scholar
  70. 70.
    Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM (2010) Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172–179PubMedCrossRefGoogle Scholar
  71. 71.
    Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, Redha E, Marin JR, Lon-Young M, Wolff GS (2004) Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 23:832–838PubMedCrossRefGoogle Scholar
  72. 72.
    Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058–1067PubMedCrossRefGoogle Scholar
  73. 73.
    Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029–1033PubMedCrossRefGoogle Scholar
  74. 74.
    Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53:105–113PubMedCrossRefGoogle Scholar
  75. 75.
    Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, Renlund DG (1995) Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129:197–199PubMedCrossRefGoogle Scholar
  76. 76.
    Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY (2007) Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298:1171–1179PubMedCrossRefGoogle Scholar
  77. 77.
    Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin A, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, DeLaat C, Steinherz LJ, Zhao H (2004) Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22:820–828PubMedCrossRefGoogle Scholar
  78. 78.
    Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O’Holleran EW, Neuberg DS, Cohen HJ, Sallan SE (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24:320–334PubMedCrossRefGoogle Scholar
  79. 79.
    Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154–171PubMedGoogle Scholar
  80. 80.
    Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837–846PubMedCrossRefGoogle Scholar
  81. 81.
    Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879PubMedCrossRefGoogle Scholar
  82. 82.
    Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, Foley B, Bourge RC (2005) Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24:2196–2201PubMedCrossRefGoogle Scholar
  83. 83.
    Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, Retief J, Sistare FD, Herman EH (2010) Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 66:303–314PubMedCrossRefGoogle Scholar
  84. 84.
    Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389–405PubMedCrossRefGoogle Scholar
  85. 85.
    Trachtenberg BH, Hare JM (2009) Biomarkers of oxidative stress in heart failure. Heart Fail Clin 5:561–577PubMedCrossRefGoogle Scholar
  86. 86.
    Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, Guerin S, Pacquement H, Aouba A, Hawkins M, Winter D, Bourhis J, Lefkopoulos D, Diallo I, de Vathaire F (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308–1315PubMedCrossRefGoogle Scholar
  87. 87.
    Unverferth DV, Jagadeesh JM, Unverferth BJ, Magorien RD, Leier CV, Balcerzak SP (1983) Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J Natl Cancer Inst 71:917–920PubMedGoogle Scholar
  88. 88.
    van WM, Neggers SJ, van der Lelij AJ, Pieters R, van den Heuvel-Eibrink MM (2010) The metabolic syndrome in adult survivors of childhood cancer, a review. J Pediatr Hematol Oncol 32:171–179CrossRefGoogle Scholar
  89. 89.
    van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2005) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 1:CD003917PubMedGoogle Scholar
  90. 90.
    van Dalen EC, Michiels EMC, Caron HN, Kremer LCM (2006) Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 4:CD005006PubMedGoogle Scholar
  91. 91.
    van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 3:CD005006PubMedGoogle Scholar
  92. 92.
    Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 62:200–208CrossRefGoogle Scholar
  93. 93.
    Wallace KB (2007) Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101–107PubMedCrossRefGoogle Scholar
  94. 94.
    Walsh JM, Hussey J, Guinan E, O'Donnell D (2010) Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population: a feasibility study PEACH trial: prescribed exercise after chemotherapy. BMC Cancer 10:42PubMedCrossRefGoogle Scholar
  95. 95.
    Williams RV, Tani LY, Shaddy RE (2002) Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 21:906–909PubMedCrossRefGoogle Scholar
  96. 96.
    Wonders KY, Reigle BS (2009) Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise. Integr Cancer Ther 8:17–21PubMedCrossRefGoogle Scholar
  97. 97.
    Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561–578PubMedCrossRefGoogle Scholar
  98. 98.
    Zhou S, Palmeira CM, Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 121:151–157PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Barry H. Trachtenberg
    • 2
  • David C. Landy
    • 2
  • Vivian I. Franco
    • 2
  • Jacqueline M. Henkel
    • 2
  • Elliot J. Pearson
    • 2
  • Tracie L. Miller
    • 1
  • Steven E. Lipshultz
    • 1
  1. 1.University of Miami Leonard M. Miller School of Medicine, Holtz Children’s Hospital of the University of Miami/Jackson Memorial Medical Center, University of Miami Sylvester Comprehensive Cancer CenterMiamiUSA
  2. 2.University of Miami Leonard M. Miller School of MedicineMiamiUSA

Personalised recommendations